COMMUNIQUÉS West-GlobeNewswire
-
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
22/09/2026 -
Cynet Announces Version 5.0 of its Platform, Unveiling New Cross-Site Dashboard and Enhanced SIEM Capabilities to Maximize Speed, Scale, and Interoperability
22/09/2026 -
CurePSP Expands Center of Care Network to Europe, Adding Eight New Institutions Worldwide
22/09/2026 -
New Research Provides Groundbreaking Look Into Brain Processes Behind PANS, PANDAS, Sydenham’s Chorea
22/09/2026 -
SK pharmteco and GEMMABio Expand Rare Disease Manufacturing Collaboration Following Important Spinal Muscular Atrophy (SMA) Clinical Trial Milestone
22/09/2026 -
TETmedical Strengthens Board of Directors with Appointment of Marc Lebel and Patrick McBrayer, Veteran Life Sciences Entrepreneurs and Company Builders
22/09/2026 -
SafeSpace Global Secures Up to $11 Million in Financing Capacity to Support Next Phase of Growth
22/09/2026 -
X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
22/09/2026 -
Porch Light Health and CBHC Expand Access to Methadone Treatment in Northern Colorado
22/09/2026 -
Eclipse Energy and Wood Validate Pathway to Low-Cost, Ultra-Low-Carbon Hydrogen from Depleted Oil Reservoirs
22/09/2026 -
New Study Reveals When College Students at Risk for Suicide Begin to Improve in Virtual Therapy
22/09/2026 -
Ophirex Publishes Data from Phase 2 BRAVIO Trial Evaluating Intravenous Followed by Oral Varespladib for Snakebite
22/09/2026 -
Seek Labs Launches Open Impact Program at Clinton Global Initiative to Advance Therapeutic Development for Neglected Infectious Diseases
22/09/2026 -
Rendever Expands Dementia & Empathy Training With a New Mode for Family Caregivers
22/09/2026 -
Kylo Peptides Strengthens U.S.-Based Supply Chain for Research Peptides with Faster Domestic Fulfillment
22/09/2026 -
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity
22/09/2026 -
SK pharmteco et GEMMABio renforcent leur collaboration dans la fabrication de traitements pour les maladies rares après une étape clé de l’essai clinique consacré à l’amyotrophie spinale (SMA)
22/09/2026 -
Applied Biologics Announces Last Patient, Last Visit in CAMPX Randomized Controlled Trial of XWRAP®
22/09/2026 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026
22/09/2026
Pages